Inhibikase Therapeutics, Inc. (IKT) has 8 SEC Form 4 insider filings on record in the last 90 days. Most recent filing: July 31, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| July 31, 2026 filed July 29, 2026 | RA CAPITAL MANAGEMENT, L.P. 10% Owner | $0 | 36,060,000 | −50% | No | |
|
|
||||||
| July 31, 2026 filed July 30, 2026 | BERMAN DENNIS N Director | $27,536 | 43,708 | — | No | |
|
|
||||||
| June 30, 2026 filed June 26, 2026 | BERMAN DENNIS N Director | $0 | 155,000 | 0% | No | |
|
|
||||||
| June 30, 2026 filed June 26, 2026 | Aurentz Vincent Director | $0 | 155,000 | 0% | No | |
|
|
||||||
| June 30, 2026 filed June 26, 2026 | Kush Arvind Director | $0 | 155,000 | 0% | No | |
|
|
||||||
Showing the 5 most recent of 8 filings in the last 90 days.
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free